Fort Point Capital Partners’s Unity Biotechnology UBX Stock Holding History

Fort Point Capital Partners’s Portfolio UBX Stock Details UBX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-1,000	Closed	-$60K	–	168
2021 Q1	$60K	Hold	1,000	–	–	0.01%	150
2020 Q4	$52K	Buy	+1,000	New	+$48.2K	0.01%	147
2020 Q3	–	Sell	-1,300	Closed	-$113K	–	151
2020 Q2	$113K	Buy	+1,300	New	+$96.4K	0.04%	124

Other funds holding UBX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Mayo Clinic Rochester, Minnesota $2.9M AUM 14.49% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

IFA

Invus Financial Advisors New York $89.2M AUM 10.79% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Fort Point Capital Partners's UBX Position: Q2 2021 in Review

Fort Point Capital Partners sold out of Unity Biotechnology (UBX) in Q2 2021, closing a stake of 1,000 shares — an estimated $60K sold.

Fort Point Capital Partners first reported a position in UBX in Q2 2020 and held it in 3 quarters. The position peaked at $113K in Q2 2020. 98 funds tracked by Wall St. Rank hold UBX as of Q2 2021.

Fort Point Capital Partners reported no remaining Unity Biotechnology position as of Q2 2021 after selling out during the quarter.
Fort Point Capital Partners sold 1,000 Unity Biotechnology shares in Q2 2021, an estimated $60K.
Fort Point Capital Partners first reported a position in Unity Biotechnology in Q2 2020 and held it in 3 quarters.
Fort Point Capital Partners's Unity Biotechnology position peaked at $113K in Q2 2020.
98 funds tracked by Wall St. Rank held Unity Biotechnology as of Q2 2021.

Based on Fort Point Capital Partners's 13F filing for Q2 2021, filed 30 Jul 2021.